Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial.
Volume: 28, Issue: 15_suppl, Pages: 1018 - 1018
Published: May 20, 2010
Abstract
1018 Background: Triple negative breast cancer (TNBC) shares molecular characteristics with BRCA1-/- breast cancer (BC). Preclinical and clinical data show that BRCA1-/- BC and TNBC are sensitive to inhibition of PARP1, an enzyme necessary for DNA repair and other critical cell functions. This phase 1 study evaluated the tolerability of olaparib, a potent PARP1 inhibitor, combined with weekly paclitaxel in patients with metastatic TNBC. This...
Paper Details
Title
Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial.
Published Date
May 20, 2010
Journal
Volume
28
Issue
15_suppl
Pages
1018 - 1018
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History